Brief: Selectimmune Pharma: Results From Clinical Study With IL-1 Receptor Inhibitors
23/04/2020 08:12
April 23 (Reuters) - Selectimmune Pharma AB SELECTb.TE :
* RESEARCHERS AT LUND UNIVERSITY ARE NOW PUBLISHING RESULTS
FROM
CLINICAL STUDY IN WHICH IL-1 RECEPTOR INHIBITORS HAVE BEEN USED
TO TREAT PATIENTS WITH CHRONIC LOWER URINARY TRACT PAIN
(INTERSTITIAL CYSTITIS)
* STUDY SHOWS STRONG POSITIVE CLINICAL EFFECTS ON SYMPTOM
AND LIFE
QUALITY
Source text for Eikon: ID:nWkrBG8b8
Further company coverage: SELECTb.TE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 587785110;))
Recent news on Selectimmune Pharma AB
See all newsBrief: Selectimmune Pharma Says Co's CEO Ann Gidner Will Leave Selectimmune Pharma
Brief: Lonza Collaborates With Selectimmune Collaborates To Develop Immunotherapeutic Drug Candidate
Brief: Selectimmune Pharma Q2 Pretax Loss Widens To SEK 3.1 Mln
Brief: Selectimmune Pharma Q1 Pretax Loss Narrows To SEK 2.2 Million
Brief: Selectimmune Pharma Signs Deal On Phase II Study For Infection Treatment